Sight Sciences, Inc. Q1 2026 Earnings Call Summary

Sight Sciences, Inc. Q1 2026 Earnings Call Summary - Moby

Strategic Performance and Market Dynamics

Achieved a return to double-digit total revenue growth driven by the third consecutive quarter of Interventional Glaucoma expansion and a near-doubling of Interventional Dry Eye revenue. Introduced the 'Intersection of Intervention' strategy, leveraging the high patient overlap between glaucoma and dry eye to drive TearCare adoption among existing OMNI customers. Interventional Dry Eye performance was bolstered by early validation of the reimbursed business model in First Coast and Novitas regions, where fee schedules were recently established. Glaucoma growth of 7% was primarily driven by increased volume and pricing, supported by the reactivation of dormant accounts and the addition of new accounts via OMNI Edge. Maintained high gross margins of 86% while significantly reducing cash usage through disciplined operating expense management and a lower cost structure following a 2025 reduction in force. Management highlighted that approximately half of all active dry eye accounts originated from the existing glaucoma customer base, showing higher utilization than dry-eye-only accounts.

2026 Outlook and Strategic Initiatives

Raised full-year 2026 revenue guidance to $83 million - $89 million, reflecting confidence in the scaling of the reimbursed dry eye business and steady glaucoma execution. Expects additional Medicare Administrative Contractors (MACs) and commercial payers to establish fee schedules for TearCare within the year based on ongoing clinical and economic data reviews. Anticipates FDA clearance for OMNI Ultra in the coming months and hopes to launch the product by year-end, though the company noted that 510(k) clearance pathways are not definitive. to further differentiate the company's implant-free surgical glaucoma portfolio. Guidance for Interventional Dry Eye ($6 million - $8 million) assumes only the current First Coast and Novitas fee schedules, representing a conservative approach to market access timing. Management remains focused on achieving cash flow breakeven without the need for additional equity capital, supported by a strong cash position of $85 million.

Legal and Structural Developments

A final judgment in the Alcon patent litigation confirmed approximately $55 million in past damages and interest, plus a 10% ongoing royalty on Hydrus revenue, though this remains subject to appeal. Operating expenses for the quarter were $29.4 million, which included the impact of a $5.4 million one-time fee earned following a successful final judgment in the Alcon litigation case.; excluding this, expenses were down 17% year-over-year. Interventional Dry Eye gross margins improved to 72% and are expected to scale further as the reimbursed model offsets absorption and overhead costs. The company established a dedicated market development team specifically to unlock the stand-alone glaucoma intervention opportunity, modeled after cataract patient workflows.

Story Continues

Q&A Session Highlights

Steady-state utilization trajectory for TearCare SmartLids

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Management stated they are not yet close to a steady state, as accounts are still in the early stages of activating the technology across their Medicare fee-for-service populations. Approximately 10% of accounts are currently driving the majority of volume, serving as a model for workflow integration that the company aims to replicate across the base.

Market access expectations and guidance assumptions for dry eye

Current 2026 guidance only includes revenue from regions with established fee schedules (First Coast and Novitas). Management expressed confidence in securing additional payer wins this year but noted that exact timing is difficult to predict as they build a new procedural category.

Competitive dynamics and market trends in Interventional Glaucoma

The company is seeing a tailwind from the ophthalmic community's shift toward earlier intervention, positioning OMNI as the leading implant-free microinvasive option. Strong performance in March followed a slower start in January and February, with momentum expected to carry through the remainder of the year.

Sales force expansion and commercial resource allocation

The dry eye team remains small (roughly 10 members at year-end) but is being incrementally expanded in regions with active reimbursement. Investments are being balanced between market access resources and clinical support to help practices establish efficient procedural workflows.

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.

View Comments